Why the study?
What is the comparative survival and cost-effectiveness of advanced therapies (OHT, LVAD) versus inotrope-dependent medical therapy in end-stage heart failure?
What is the comparative survival and cost-effectiveness of advanced therapies (OHT, LVAD) versus inotrope-dependent medical therapy in end-stage heart failure?
OHT is cost-effective for eligible patients, while LVAD as destination therapy or bridge to transplant significantly improves survival but exceeds conventional cost-effectiveness thresholds.
No takes yet. Share an insight, caveat, or question.
Supports OHT prioritization in eligible patients; leaves open LVAD value amid high costs and evolving outcomes.
Long et al. (2014) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: